Substituted indole derivatives for the treatment of immunological disorders,WO 2012156936, Novartis AG, Protein kinase C theta inhibitor

TITLE-Substituted indole derivatives for the treatment of immunological disorders

Protein kinase C theta inhibitor

WO 2012156936, 22.11.2012, Novartis AG

GENERAL STRUCTURE

DESCRIBED IS

Phosphoric acid mono-[3-[3-(4,7-diaza-spiro[2.5]oct-7-yl)-isoquinolin-1 -yl]-4-(7-methyl-1 H-indol-3-yl)-2,5-dioxo-2,5-dihydro-pyrrol-1 -ylmethyl] ester

¹H-NMR (400 MHz, DMSO-d6): 12.10 (s, 1 H), 8.08 (d, 1 H), 7.65-7.61 (m, 2H), 7.44 (f, 1 H), 7.20 (s, 1 H), 7.06 (f, 1 H), 6.74 (d, 1 H), 6.43 (f, 1 H), 6.00 (d, 1 H), 5.29 (d, 2H), 3.87-3.01 (m, 6H), 2.37 (s, 3H), 0.97-0.62 (m, 4H).

³¹P-NMR (162 MHz, DMSO-d6): -6.0.

LCMS: [M+1]⁺ = 574.0, Rt ⁽¹⁾ = 1.77 min., Rt ⁽²⁾ = 0.71 min.

Descibed is a  crystalline form of phosphoric acid mono-[3-[3-(4,7-diaza-spiro[2.5]oct-7-yl)-isoquinolin-1- yl]-4-(7-methyl-1 H-indol-3-yl)-2,5-dioxo-2,5-dihydro-pyrrol-1-ylmethyl] ester, especially the mono-hydrate, which preferably has an X-ray powder diffraction pattern with at least one, preferably two, more preferably three, even more preferably four, especially five, most preferably all of the following peaks at an angle of refraction 2 theta (Θ) of 9.525, 16.356, 17.091 , 18.005, 20.859, each ± 0.2

Share this: